

Challenges in diagnosing pheochromocytoma in a patient with a long-term hypertension
https://doi.org/10.33667/2078-5631-2024-35-15-19
Abstract
Pheochromocytoma is a rare neuroendocrine tumor that produces catecholamines. Despite the obvious clinical manifestations, there are difficulties in diagnosing it, since the classic symptoms are not always found or may not be obvious. The article presents a clinical case of a patient with pheochromocytoma and a history of hypertension. The pathogenesis and diagnostic features are described, as well as clinical characteristics indicating secondary arterial hypertension. The morphological picture, management tactics of the patient and his condition in the postoperative period are demonstrated.
About the Authors
A. E. PokrovskayaRussian Federation
Pokrovskaya Anna E., PhD Med, associate professor at Dept of Faculty Therapy No. 2
Moscow
T. S. Vargina
Russian Federation
Vargina Tatyana S., PhD Med, associate professor at Dept of Faculty Therapy No. 2
Moscow
E. V. Goncharova
Russian Federation
Goncharova Ekaterina V., PhD Med, associate professor at Dept of Endocrinology
Moscow
I. D. Khutkina
Russian Federation
Khutkina Inessa D., 5th-year student of group 701–34 at the Institute of Clinical Medicine
Moscow
A. A. Kurnosova
Russian Federation
Kurnosova Anna A., 4th-year student of group 701–19 at the Institute of Clinical Medicine
Moscow
V. A. Yumasheva
Russian Federation
Yumasheva Valentina A., 5th-year student of group 701–39 at the Institute of Clinical Medicine
Moscow
V. V. Lezhneva
Russian Federation
Lezhneva Victoria V., 5th year student of group 701–503 at the Institute of Clinical Medicine
Moscow
N. V. Pachuashvili
Russian Federation
Pachuashvili Nano V., resident at the Institute of Clinical Morphology and Digital Pathology
Moscow
References
1. https://www.who.int/news-room/fact-sheets/detail/hypertension
2. Kobalava Zh.D., Konradi A. O., Nedogoda S. V., Shlyakhto E. V., Arutyunov G. P., Baranova E. I., Barbarash O. L., Boytsov S. A., Vavilova T. V., Villevalde S. V., Galyavich A. S., Glezer M. G., Grineva E. N., Grinshtein Yu.I., Drapkina O. M., Zhernakova Yu.V., Zvartau N. E., Kislyak O. A., Koziolova N. A., Kosmacheva E. D., Kotovskaya Yu.V., Libis R. A., Lopatin Yu.M., Nebieridze D. V., Nedoshivin A. O., Ostroumova O. D., Oshchepkova E. V., Ratova L. G., Skibitsky V. V., Tkacheva O. N., Chazova I. E., Chesnikova A. I., Chumakova G. A., Shalnova S. A., Shestakova M. V., Yakushin S. S., Yanishevsky S. N. Arterial hypertension in adults. Clinical guidelines 2020. Russian journal of cardiology. 2020;25(3):3786. (In Russ.). https://doi.org/10.15829/1560-4071-2020-3-3786
3. Sarathy H, Salman LA, Lee C, Cohen JB. Evaluation and Management of Secondary Hypertension. Med Clin North Am. 2022;106(2):269–283. (In Russ.). https://doi.org/10.1016/j.mcna.2021.11.004
4. Charles L, Triscott J, Dobbs B. Secondary Hypertension: Discovering the Underlying Cause. Am Fam Physician. 2017;96(7):453–461. (https://www.aafp.org/pubs/afp/issues/2017/1001/p453.html)
5. de Freminville JB, Amar L. How to Explore an Endocrine Cause of Hypertension. J Clin Med. 2022;11(2):420. Published 2022 Jan 14. https://doi.org/10.3390/jcm11020420
6. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen?. Eur Heart J. 2014;35(19):1245–1254. https://doi.org/10.1093/eurheartj/eht534
7. Siru R, Conradie JH, Gillett MJ, Page MM. Approach to the diagnosis of secondary hypertension in adults [published correction appears in Aust Prescr. 2022 Oct;45(5):183]. Aust Prescr. 2021;44(5):165–169. https://doi.org/10.18773/austprescr.2021.038
8. Kulkarni S, Glover M, Kapil V, et al. Management of hypertensive crisis: British and Irish Hypertension Society Position document. J Hum Hypertens. 2023;37(10):863–879. https://doi.org/10.1038/s41371-022-00776-9
9. Melcescu E, Koch CA. Endocrine Hypertension. In: Feingold KR, Anawalt B, Blackman MR, et al., eds. Endotext. South Dartmouth (MA): MDText.com, Inc.; October 11, 2019.
10. Zelinka T, Petrák O, Turková H, et al. High incidence of cardiovascular complications in pheochromocytoma. Horm Metab Res. 2012;44(5):379–384. https://doi.org/10.1055/s-0032–1306294
11. Carey RM, Calhoun DA, Bakris GL, et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018;72(5): e53-e90. https://doi.org/10.1161/HYP.0000000000000084
12. Al Subhi AR, Boyle V, Elston MS. Systematic Review: Incidence of Pheochromocytoma and Paraganglioma Over 70 Years. J Endocr Soc. 2022;6(9): bvac105. Published 2022 Jul 3. https://doi.org/10.1210/jendso/bvac105
13. Lima JV Júnior, Kater CE. The Pheochromocytoma/Paraganglioma syndrome: an overview on mechanisms, diagnosis and management. Int Braz J Urol. 2023;49(3):307–319. https://doi.org/10.1590/S1677–5538.IBJU.2023.0038
14. Gupta PK, Marwaha B. Pheochromocytoma. In: StatPearls. Treasure Island (FL): StatPearls Publishing; March 5, 2023.
15. Fernandez CJ, Nagendra L, Alkhalifah M, Pappachan JM. Endocrine Hypertension: The Urgent Need for Greater Global Awareness. touchREV Endocrinol. 2023;19(2):31–41. https://doi.org/10.17925/EE.2023.19.2.11
16. Mete O., Asa S. L., Gill A. J. et al. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol. 2022 Mar;33(1):90–114. https://doi.org/10.1007/s12022-022-09704-6
17. Lenders JWM, Kerstens MN, Amar L, et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020;38(8):1443–1456. https://doi.org/10.1097/HJH.0000000000002438
18. Prejbisz A, Lenders JW, Eisenhofer G, Januszewicz A. Cardiovascular manifestations of phaeochromocytoma. J Hypertens. 2011;29(11):2049–2060. https://doi.org/10.1097/HJH.0b013e32834a4ce9
19. Geroula A, Deutschbein T, Langton K. et al. Pheochromocytoma and paraganglioma: Clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion. Eur J Endocrinol. 2019;181:409–20. https://doi.org/10.1530/EJE-19–0159
20. Neumann HPH, Tsoy U, Bancos I, et al. Comparison of Pheochromocytoma-Specific Morbidity and Mortality Among Adults With Bilateral Pheochromocytomas Undergoing Total Adrenalectomy vs Cortical-Sparing Adrenalectomy. JAMA Netw Open. 2019;2(8): e198898. Published 2019 Aug 2. https://doi.org/10.1001/jamanetworkopen.2019.8898
21. Chazova I.E., Chikhladze N.M., Blinova N.V., Belaya Zh.E., Danilov N.M., Elfimova E.M., Litvin A.Yu., Rozhinskaya L.Ya., Sviridenko N.Yu., Shvetsov M.Yu., Azizov V.A., Grigorenko E.A., Mitkovskaya N.P., Mustafaev I.I., Polupanov A.G., Sarybaev A.Sh., Khamidullaeva G.A. Eurasian clinical guidelines for the diagnosis and treatment of secondary (symptomatic) forms of arterial hypertension (2022). Eurasian Journal of Cardiology. 2023;(1):6-65. (In Russ.). https://doi.org/10.38109/2225-1685-2023-1-6-65
22. Naghshineh H, Hasanpour A, Ziaei N, Sadeghi M, Meftah N. Pheochromocytoma triggered by coronavirus disease 2019: a case report. J Med Case Rep. 2022;16(1):233. Published 2022 Jun 10. https://doi.org/10.1186/s13256-022-03378-8
Review
For citations:
Pokrovskaya A.E., Vargina T.S., Goncharova E.V., Khutkina I.D., Kurnosova A.A., Yumasheva V.A., Lezhneva V.V., Pachuashvili N.V. Challenges in diagnosing pheochromocytoma in a patient with a long-term hypertension. Medical alphabet. 2024;(35):15-19. (In Russ.) https://doi.org/10.33667/2078-5631-2024-35-15-19